nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.06.2021 | Opinion

Block-and-replace vs. titration antithyroid drug regimen for Graves’ hyperthyroidism: two is not always better than one

verfasst von: L. H. Duntas

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Excerpt

In the early 1940s, Astwood’s pioneering use of thionamides as antithyroid drugs provided a reliable therapeutic alternative to surgery, which, at the time, represented the only treatment option for hyperthyroidism [1, 2]. Today, methimazole (1-methyl-2-mercaptoimidazole; MMI) and propylthiouracil (6-propyl-2-thiouracil; PTU) are the most frequently used antithyroid drugs (ATDs) in Europe and in the USA, a pro-drug of methimazole, carbimazole, generally being less prescribed [3]. ATDs inhibit thyroid hormone synthesis by binding to thyroid peroxidase competitively with iodide, thus inhibiting the oxidation of iodide as well as the iodination of tyrosyl residues in thyroglobulin and preventing their coupling to form iodothyronines [4]. In addition, PTU, inhibits only the deiodination of L-thyroxine (LT4) to L-triiodothyronine (LT3) [5]. …

Astwood EB (1984) Landmark article May 8, 1943: treatment of hyperthyroidism with thiourea and thiouracil. JAMA 251:1743–1746. https://doi.org/10.1001/jama.251.13.1743CrossRefPubMed

Burch HB, Cooper DS (2018) Anniversary review: antithyroid drug therapy: 70 years later. Eur J Endocrinol 179:R261–R274. https://doi.org/10.1530/EJE-18-0678CrossRefPubMed

Cooper DS (2005) Antithyroid drugs. New Engl J Med 352:905–917. https://doi.org/10.1056/NEJMra042972CrossRefPubMed

Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP, Koutras DA (2000) Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves’ disease. Thyroid 10:527–532. https://doi.org/10.1089/thy.2000.10.527CrossRefPubMed

Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I (1987) Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves’ disease. N Engl J Med 316:15–22. https://doi.org/10.1056/NEJM198701013160104CrossRefPubMed

Wise PH, Marion M, Pain RW (1973) Single dose, “block-replace” drug therapy in hyperthyroidism. Br Med J 4(5885):143–145. https://doi.org/10.1136/bmj.4.5885.143CrossRefPubMedPubMedCentral

Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T (1991) Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 324(14):947–953. https://doi.org/10.1056/NEJM199104043241403CrossRefPubMed

Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM (1994) Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 87:337–341PubMed

Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS (2010) Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 1:CD003420. https://doi.org/10.1002/14651858.CD003420.pub4CrossRef

10.

Žarković M, Wiersinga W, Perros P, Bartalena L, Donati S, Okosieme O, Morris D, Fichter N, Lareida J, Daumerie C, Burlacu MC, Kahaly GJ, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Törüner FB, Salvi M, Covelli D, Curro N, Hegedüs L, Brix T, EUGOGO (European Group on Graves’ Orbitopathy) (2020) Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment. J Endocrinol Invest. https://doi.org/10.1007/s40618-020-01320-7CrossRefPubMedPubMedCentral

11.

Laurberg P, Berman DC, Andersen S, Bülow PI (2011) Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid 21:951–956. https://doi.org/10.1089/thy.2011.0039CrossRefPubMed

12.

McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A (1996) Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 334:220–224. https://doi.org/10.1056/NEJM199601253340403CrossRefPubMed

13.

Grebe SK, Feek CM, Ford HC, Fagerstrom JN, Cordwell DP, Delahunt JW et al (1998) A randomized trial of short-term treatment of Graves' disease with high- dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol 48:585–592CrossRef

14.

Glinoer D, Nayer P, Bex M, Belgian CS (2001) Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475–483CrossRef

15.

Edmonds CJ, Tellez M (1994) Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose. Eur J Endocrinol 131:120–124. https://doi.org/10.1530/eje.0.1310120CrossRefPubMed

16.

Vaidya B, Wright A, Shuttleworth J, Donohoe M, Warren R, Brooke A, Gericke CA, Ukoumunne OC (2014) Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves' disease: a retrospective observational study. Clin Endocrinol (Oxf). 81(4):610–613. https://doi.org/10.1111/cen.12478CrossRefPubMed

17.

Vigone MC, Peroni E, Di Frenna M, Mora S, Barera G, Weber G (2020) “Block-and-replace” treatment in Graves’ disease: experience in a cohort of pediatric patients. J Endocrinol Invest 43:595–600. https://doi.org/10.1007/s40618-019-01144-0CrossRefPubMed

18.

Volpe R (2001) The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Cur Pharmac Design 7:451–460CrossRef

19.

Azizi F, Malboosbaf R (2019) Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest 42:1273–1283CrossRef

20.

Francis N, Francis T, Lazarus JH, Okosieme OE (2020) Current controversies in the management of Graves' hyperthyroidism. Expert Rev Endocrinol Metab 15:159–169. https://doi.org/10.1080/17446651.2020.175419CrossRefPubMed

Titel: Block-and-replace vs. titration antithyroid drug regimen for Graves’ hyperthyroidism: two is not always better than one
verfasst von: L. H. Duntas
Publikationsdatum: 01.06.2021
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 6/2021
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-020-01431-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Block-and-replace vs. titration antithyroid drug regimen for Graves’ hyperthyroidism: two is not always better than one

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Identification of four novel variant in the AMHR2 gene in six unrelated Turkish families

Alterations of gut microbiota composition in post-finasteride patients: a pilot study

Plasma dosage of ghrelin, IGF-1, GLP- 1 and leptin related to gastric emptying and esophageal pH-impedance in children with obesity

MiR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20

Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype

Tissue and circulating microRNAs as biomarkers of response to obesity treatment strategies

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin